{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:08:37Z","timestamp":1773918517809,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002799","name":"Capital Medical University","doi-asserted-by":"publisher","award":["2021ZZLX03"],"award-info":[{"award-number":["2021ZZLX03"]}],"id":[{"id":"10.13039\/501100002799","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemistry and Biophysics Reports"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bbrep.2025.102364","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T22:14:12Z","timestamp":1764627252000},"page":"102364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Alterations of the tumor microenvironment (TME) by exploratory gene expression analysis in recurrent glioblastoma following apatinib in combination with temozolomide"],"prefix":"10.1016","volume":"45","author":[{"given":"Jingjing","family":"Ge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengjun","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenchen","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaopei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9827-0580","authenticated-orcid":false,"given":"Junping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.bbrep.2025.102364_bib1","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/neuonc\/not151","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010","volume":"15","author":"Ostrom","year":"2013","journal-title":"Neuro Oncol."},{"issue":"4","key":"10.1016\/j.bbrep.2025.102364_bib2","first-page":"299","article-title":"Management of glioblastoma: state of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102364_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4103\/glioma.glioma_6_22","article-title":"Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: a prospective, phase II, single-arm study","volume":"5","author":"Lin","year":"2022","journal-title":"Glioma"},{"issue":"6","key":"10.1016\/j.bbrep.2025.102364_bib4","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1016\/j.cllc.2018.06.002","article-title":"A phase II clinical trial of apatinib in pretreated advanced non-squamous non-small-cell lung cancer","volume":"19","author":"Wu","year":"2018","journal-title":"Clin. Lung Cancer"},{"issue":"4","key":"10.1016\/j.bbrep.2025.102364_bib5","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","article-title":"Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial","volume":"27","author":"Xu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrep.2025.102364_bib6","article-title":"Apatinib plus temozolomide: an effective salvage treatment for recurrent glioblastoma","volume":"10","author":"Ge","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrep.2025.102364_bib7","doi-asserted-by":"crossref","first-page":"10579","DOI":"10.2147\/OTT.S226804","article-title":"Apatinib plus temozolomide for recurrent glioblastoma: an uncontrolled, open-label study","volume":"12","author":"Wang","year":"2019","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.bbrep.2025.102364_bib8","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jocn.2021.05.032","article-title":"Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas","volume":"90","author":"Yao","year":"2021","journal-title":"J. Clin. Neurosci."},{"issue":"5","key":"10.1016\/j.bbrep.2025.102364_bib9","first-page":"5607","article-title":"Apatinib suppresses cell growth and metastasis and promotes antitumor activity of temozolomide in glioma","volume":"16","author":"Wang","year":"2018","journal-title":"Oncol. Lett."},{"issue":"17","key":"10.1016\/j.bbrep.2025.102364_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24173046","article-title":"Next generation sequencing-based transcriptome predicts Bevacizumab efficacy in combination with temozolomide in glioblastoma","volume":"24","author":"Adilijiang","year":"2019","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.bbrep.2025.102364_bib11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/cas.13889","article-title":"Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab","volume":"110","author":"Tamura","year":"2019","journal-title":"Cancer Sci."},{"issue":"11","key":"10.1016\/j.bbrep.2025.102364_bib12","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.bbrep.2025.102364_bib13","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and Bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102364_bib14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1089\/thy.2019.0650","article-title":"Molecular determinants of thyroid nodules with indeterminate cytology and RAS mutations","volume":"31","author":"Hernandez-Prera","year":"2021","journal-title":"Thyroid"},{"issue":"11","key":"10.1016\/j.bbrep.2025.102364_bib15","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/bioinformatics\/bts188","article-title":"NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data","volume":"28","author":"Waggott","year":"2012","journal-title":"Bioinformatics"},{"issue":"12","key":"10.1016\/j.bbrep.2025.102364_bib16","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"issue":"18","key":"10.1016\/j.bbrep.2025.102364_bib17","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"issue":"4","key":"10.1016\/j.bbrep.2025.102364_bib18","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","article-title":"Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer","volume":"39","author":"Bindea","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.bbrep.2025.102364_bib19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40425-017-0215-8","article-title":"Gene expression markers of Tumor infiltrating leukocytes","volume":"5","author":"Danaher","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.bbrep.2025.102364_bib20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"},{"issue":"8","key":"10.1016\/j.bbrep.2025.102364_bib21","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102364_bib22","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/s12967-019-2100-3","article-title":"The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort","volume":"17","author":"Damotte","year":"2019","journal-title":"J. Transl. Med."},{"issue":"6322","key":"10.1016\/j.bbrep.2025.102364_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf8399","article-title":"Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy","volume":"355","author":"Davoli","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bbrep.2025.102364_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40425-018-0472-1","article-title":"A gene expression assay for simultaneous measurement of microsatellite instability and anti-tumor immune activity","volume":"7","author":"Danaher","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bbrep.2025.102364_bib25","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol."},{"issue":"7559","key":"10.1016\/j.bbrep.2025.102364_bib26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.bbrep.2025.102364_bib27","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.clon.2015.07.004","article-title":"Gene expression signatures as biomarkers of tumour hypoxia","volume":"27","author":"Harris","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"7","key":"10.1016\/j.bbrep.2025.102364_bib28","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/annonc\/mdw181","article-title":"Biomarkers associated with checkpoint inhibitors","volume":"27","author":"Manson","year":"2016","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102364_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12253-015-9989-5","article-title":"Effect of concomitant radiochemotherapy on invasion potential of glioblastoma","volume":"22","author":"Hutoczki","year":"2016","journal-title":"Pathol. Oncol. Res."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102364_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151815","article-title":"Comparative analysis of matrix metalloproteinase family members reveals that MMP9 predicts survival and response to temozolomide in patients with primary glioblastoma","volume":"11","author":"Li","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bbrep.2025.102364_bib31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102364_bib32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","article-title":"Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity","volume":"2","author":"Ackerman","year":"2021","journal-title":"Nat. Cancer"},{"issue":"15","key":"10.1016\/j.bbrep.2025.102364_bib33","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1158\/1078-0432.CCR-25-0595","article-title":"FDA approval summary: afamitresgene autoleucel for adults with HLA-Restricted, MAGE-A4-Positive unresectable or metastatic synovial sarcoma after prior chemotherapy","volume":"31","author":"Barnett","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrep.2025.102364_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102891","article-title":"Melanoma-associated antigen A4: a cancer\/testis antigen as a target for adoptive T-cell receptor T-cell therapy","volume":"134","author":"Knafler","year":"2025","journal-title":"Cancer Treat Rev."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102364_bib35","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4103\/glioma.glioma_12_22","article-title":"Progress on TTFields combined with other therapies for glioblastoma treatment: a narrative review","volume":"5","author":"Cao","year":"2022","journal-title":"Glioma"},{"issue":"5","key":"10.1016\/j.bbrep.2025.102364_bib36","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.bbrep.2025.102364_bib37","first-page":"CD008218","article-title":"Anti-angiogenic therapy for high-grade glioma","volume":"11","author":"Ameratunga","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.bbrep.2025.102364_bib38","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s12272-020-01232-3","article-title":"Small molecule tyrosine kinase inhibitors in glioblastoma","volume":"43","author":"Kim","year":"2020","journal-title":"Arch Pharm. Res. (Seoul)"},{"issue":"8","key":"10.1016\/j.bbrep.2025.102364_bib39","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.bbrep.2025.102364_bib40","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1200\/JCO.2015.61.5005","article-title":"Patients with proneural glioblastoma may derive overall survival benefit from the addition of Bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial","volume":"33","author":"Sandmann","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bbrep.2025.102364_bib41","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/neuonc\/nou356","article-title":"Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study","volume":"17","author":"Nabors","year":"2015","journal-title":"Neuro Oncol."},{"issue":"suppl_6","key":"10.1016\/j.bbrep.2025.102364_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/now212.018","article-title":"ACTR-19. Baseline plasma matrix metalloproteinase 9 (MMP9) predicts overall survival (OS) benefit from bevacizumab independently of molecular subtypes in newly diagnosed glioblastoma: RETROSPECTIVE ANALYSIS OF AVAglio","volume":"18","author":"Chinot","year":"2016","journal-title":"Neuro Oncol."},{"issue":"12","key":"10.1016\/j.bbrep.2025.102364_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26125892","article-title":"Analysis of the expression patterns of tumor necrosis factor alpha signaling pathways and regulatory MicroRNAs in astrocytic tumors","volume":"26","author":"Sk\u00f3ra","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.bbrep.2025.102364_bib44","doi-asserted-by":"crossref","first-page":"297","DOI":"10.21037\/atm.2020.03.11","article-title":"Alterations of the tumor microenvironment in glioblastoma following radiation and temozolomide with or without bevacizumab","volume":"8","author":"Tamura","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.bbrep.2025.102364_bib45","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3389\/fonc.2018.00656","article-title":"Harnessing radiation biology to augment immunotherapy for glioblastoma","volume":"8","author":"Rajani","year":"2018","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102364_bib46","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13046-021-02069-4","article-title":"Apatinib triggers autophagic and apoptotic cell death via VEGFR2\/STAT3\/PD-L1 and ROS\/Nrf2\/p62 signaling in lung cancer","volume":"40","author":"Xie","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102364_bib47","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/10717544.2020.1754528","article-title":"Enhancing the chemotherapy effect of Apatinib on gastric cancer by co-treating with salidroside to reprogram the tumor hypoxia micro-environment and induce cell apoptosis","volume":"27","author":"Zhang","year":"2020","journal-title":"Drug Deliv."},{"issue":"8","key":"10.1016\/j.bbrep.2025.102364_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.422","article-title":"Apatinib promotes autophagy and apoptosis through VEGFR2\/STAT3\/BCL-2 signaling in osteosarcoma","volume":"8","author":"Liu","year":"2017","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102364_bib49","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10456-020-09716-y","article-title":"Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself","volume":"23","author":"Yang","year":"2020","journal-title":"Angiogenesis"},{"issue":"7","key":"10.1016\/j.bbrep.2025.102364_bib50","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126140","article-title":"Chromatin remodeler HELLS maintains glioma stem cells through E2F3 and MYC","volume":"4","author":"Zhang","year":"2019","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.bbrep.2025.102364_bib51","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1158\/0008-5472.CAN-18-0482","article-title":"Drak\/STK17A drives neoplastic glial proliferation through modulation of MRLC signaling","volume":"79","author":"Chen","year":"2019","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bbrep.2025.102364_bib52","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41418-022-01104-x","article-title":"Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma","volume":"30","author":"Cao","year":"2023","journal-title":"Cell Death Differ."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102364_bib53","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11060-008-9579-4","article-title":"Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR","volume":"88","author":"Scrideli","year":"2008","journal-title":"J. Neuro Oncol."},{"issue":"7","key":"10.1016\/j.bbrep.2025.102364_bib54","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41419-021-03911-5","article-title":"Circular RNA hsa_circ_0000277 sequesters miR-4766-5p to upregulate LAMA1 and promote esophageal carcinoma progression","volume":"12","author":"Zhou","year":"2021","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102364_bib55","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.3892\/ol.2016.4171","article-title":"High expression of UBE2C is associated with the aggressive progression and poor outcome of malignant glioma","volume":"11","author":"Ma","year":"2016","journal-title":"Oncol. Lett."}],"container-title":["Biochemistry and Biophysics Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580825004510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580825004510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:10:43Z","timestamp":1773900643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405580825004510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":55,"alternative-id":["S2405580825004510"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrep.2025.102364","relation":{},"ISSN":["2405-5808"],"issn-type":[{"value":"2405-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alterations of the tumor microenvironment (TME) by exploratory gene expression analysis in recurrent glioblastoma following apatinib in combination with temozolomide","name":"articletitle","label":"Article Title"},{"value":"Biochemistry and Biophysics Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrep.2025.102364","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102364"}}